Release date: 2015-10-08
Fosun Pharma
The holding subsidiary Guilin South Medicine Artesunate was officially approved by WHO-PQ in 2010. Three of the five compounds recommended by WHO include artesunate, and the innovative drug Artesun (artesunate for injection) is global. The first initiative has become the drug of choice for the treatment of severe malaria, which is highly recommended by WHO. In 2014, sales of Fuxing artesunate drugs exceeded RMB 200 million.
Kunming Pharmaceutical Group
Kunming Medicine is a supplier of raw materials for Novartis Artemisia, and has the approval for the production of artemether injection. On September 29, Kunming completed the acquisition of Huafang Ketai and obtained artemisinin such as dihydroartemisinin and piperacil. Class products. At present, Kunming Medicine Artemether Injection and Dihydro Artemisinin Praperazine Tablets (Ketai Fu) are applying for WHO-PQ certification.
Zhejiang Medicine
Novartis Coartem (artemether + sterol) is a supplier of sterol, and there is a batch of artemether raw materials.
Xinhecheng
With artesunate preparation and raw materials, dihydroartemisinin preparation approval.
China Resources Double Crane
With the approval of the dihydroartemisinin preparation.
Baiyun Mountain
There is an artemisinin approval.
Wang Xuehai, Chairman of Renfu Medicine:
I have seen the interpretation and extension of the online audience from different angles, especially the academician selection system and the development of Chinese medicine. I would like to say a few facts: 1. The result of Professor Tu’s award is 40 years ago, that is, the “Cultural Revolutionâ€. The results of the period. This award does not mean that China's scientific research level has reached the world's leading level after more than 30 years of reform and opening up. 2. The discovery of artemisinin is a political task and the result of collective collaboration under the national system. Professor Tu is one of the most outstanding representatives, but not her own independent invention. She also admitted that this is her greatest point. . 3. There are many problems in the academician system in China. However, the example of Professor Tu is not typical. According to my incomplete understanding, Professor Tu did not see any new important results in the 40 years after artemisinin. 4. Artemisinin has a relationship with traditional Chinese medicine, but it has little relationship. It is a plant extract, not a traditional Chinese medicine. 5. Artemisinin is an invention of China, but it does not form a Chinese industry. In the 1970s, there was no patent application. Later, the patent for artemether of the Academy of Military Medical Sciences was transferred to the Novartis company in 1994, which allowed it to monopolize the global market. It is still restricting the artemisinin planting and extraction industry in China. 6. We must learn from the dedication of the predecessors such as Professor Tu, and stand on their own and truly enhance the level of biomedical technology in China!
Wang Junping, General Manager of Shanghai General Pharmaceutical Co., Ltd.:
At present, the first choice treatment for severe malaria in the world is the artesunate injection invented by Liu Xu of Guilin South Medicine. The variety passed the WHO-PQ certification in 2010 and is currently one of the most important anti-malarial drugs purchased by the WHO and public funds. . The invention of artesunate is one of the important achievements after artemisinin and one of China's important contributions to the world against malaria. It should be around August 2010, Professor Tu through the SFDA Director Zhang Wei found Fosun, hope to cooperate in the development of dihydroartemisinin to increase indications. At that time, President Fu of Fosun Technology Center and I went to the office of Professor Tu to talk about cooperation. Professor Tu’s office is about 15 square meters, which is a bit messy. It feels like a college teaching and research section. Professor Tu is very straightforward and very peaceful. He is a very simple old intellectual. When I left Guilin South Medicine, the project was still under negotiation. Unfortunately, the cooperation was not discussed, the reason is not clear.
Wang Licheng, the controlling shareholder of Kunming Pharmaceutical and the chairman of the board of Huali Group:
Upon hearing this news, I am very happy on the one hand, and I am proud that the Chinese have finally won this late affirmation, but more is repressed, a world-recognized Chinese invention and creation, China is at the source of raw materials. There is absolute control advantage, but it is still a supplier of cheap raw materials in the market. At most, it is the supporting role and supplement of the market for preparation products, which has to be sad. If we can support the artemisinin industry in the past few years, we can stop the spoilers in the industry in a timely manner. We can implement the strategy more effectively and efficiently. Today China should not be in this position in the global antimalarial market. .
Source: First Financial Daily
YokeLink supply a vast range of Industrial Fasteners to DIN, ISO & ANSI standards, including: Nuts, Bolts, Screws, Washers .There are hundreds of combinations of materials, heads, threads, plating, heat treating, and secondary operations. The materials and finishes including Steel, Brass, Stainless Steel, Aluminum, Zinc plating, Galvanized and Black. Providing standard and specialised Fastener solutions, coupled with industry customers. We also have the flexibility, capacity and expertise to manufacture fully customised fasteners specific to your application.
Industrial Fastener, Hex Bolts, Screws, Flange Bolts, Structural Bolts
Ningbo Yokelink Machinery Co.,Limited , https://www.yokelink.com